Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants

Merck (MRK) received FDA approval for Enflonsia, a long-acting monoclonal antibody for RSV prevention in infants, based on positive phase IIb/III CLEVER study data demonstrating reduced RSV incidence and hospitalizations; the drug is priced at $556 per dose and will be available ahead of the 2025-26 RSV season. Enflonsia will compete with AstraZeneca/Sanofi's Beyfortus, which achieved blockbuster status in its first year, as Sanofi plans to increase Beyfortus supply. Separately, Merck's oral PCSK9 inhibitor, enlicitide decanoate, met endpoints in two phase III hyperlipidemia studies.

Analysis

Merck has achieved a significant regulatory milestone with the U.S. Food and Drug Administration's (FDA) approval of Enflonsia (clesrovimab), its long-acting monoclonal antibody for Respiratory Syncytial Virus (RSV) prevention in infants, a decision that notably arrived well ahead of the previously announced target date of June 10, 2025. This approval is underpinned by positive data from the pivotal phase IIb/III CLEVER study, which demonstrated Enflonsia's efficacy in significantly reducing RSV disease incidence and related hospitalizations in healthy preterm and full-term infants. Merck intends to launch Enflonsia in the United States prior to the 2025-26 RSV season, with orders anticipated to commence next month, and has indicated a price of $556 per dose. Despite this positive development, which carries a very positive sentiment score of 0.8 for MRK, Enflonsia will enter a competitive market, directly challenging AstraZeneca and Sanofi’s Beyfortus. Beyfortus, approved for a similar indication in 2023, rapidly achieved blockbuster status in its first full year of sales in 2024, and Sanofi is already taking aggressive steps to increase its supply. While Pfizer's Abrysvo also offers infant RSV protection, it functions via maternal immunization, differing from the direct administration method of Enflonsia and Beyfortus. Compounding the competitive pressures, Merck's stock has significantly underperformed year-to-date, registering a 20% loss compared to a 1% decline for its industry. Separately, Merck also reported positive topline results from two Phase III studies (CORALreef HeFH and CORALreef AddOn) for its investigational oral PCSK9 inhibitor, enlicitide decanoate, which met primary and key secondary endpoints by showing statistically significant reductions in LDL-C in adults with hyperlipidemia.

Key Decisions for Investors

• Investors should recognize the FDA approval of Enflonsia as a key positive catalyst for Merck, offering a new revenue opportunity in the infant RSV market, with the $556 per dose pricing and execution of the launch ahead of the 2025-26 season being critical factors to monitor.
• It is crucial to closely evaluate the intense competitive landscape, particularly the established market presence and proactive supply expansion of AstraZeneca/Sanofi's Beyfortus, which will pose a direct challenge to Enflonsia's market penetration and potential pricing power.
• The successful Phase III results for enlicitide decanoate strengthen Merck's late-stage pipeline and offer long-term diversification, however, investors should also weigh the company's notable stock underperformance year-to-date, which has seen its shares decline by 19 percentage points more than the industry despite these positive clinical advancements.